- Home
- MAX vs PLRX Comparison
MAX vs PLRX Comparison
Compare MAX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- PLRX
- Stock Information
- Founded
- MAX 2014
- PLRX 2015
- Country
- MAX United States
- PLRX United States
- Employees
- MAX N/A
- PLRX N/A
- Industry
- MAX Industrial Machinery/Components
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- PLRX Health Care
- Exchange
- MAX Nasdaq
- PLRX Nasdaq
- Market Cap
- MAX 613.7M
- PLRX 641.5M
- IPO Year
- MAX 2020
- PLRX 2020
- Fundamental
- Price
- MAX $11.23
- PLRX $12.63
- Analyst Decision
- MAX Buy
- PLRX Strong Buy
- Analyst Count
- MAX 8
- PLRX 7
- Target Price
- MAX $22.00
- PLRX $40.50
- AVG Volume (30 Days)
- MAX 485.1K
- PLRX 562.1K
- Earning Date
- MAX 02-18-2025
- PLRX 02-26-2025
- Dividend Yield
- MAX N/A
- PLRX N/A
- EPS Growth
- MAX N/A
- PLRX N/A
- EPS
- MAX 0.19
- PLRX N/A
- Revenue
- MAX $681,230,000.00
- PLRX N/A
- Revenue This Year
- MAX $124.41
- PLRX N/A
- Revenue Next Year
- MAX $31.11
- PLRX N/A
- P/E Ratio
- MAX $59.43
- PLRX N/A
- Revenue Growth
- MAX 72.47
- PLRX N/A
- 52 Week Low
- MAX $10.21
- PLRX $10.22
- 52 Week High
- MAX $25.78
- PLRX $18.92
- Technical
- Relative Strength Index (RSI)
- MAX 46.18
- PLRX 46.03
- Support Level
- MAX $10.28
- PLRX $11.02
- Resistance Level
- MAX $11.83
- PLRX $13.71
- Average True Range (ATR)
- MAX 0.49
- PLRX 0.79
- MACD
- MAX 0.09
- PLRX -0.15
- Stochastic Oscillator
- MAX 58.70
- PLRX 49.77
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.